JS Link, Inc. (KOSDAQ:127120)

Market Cap	679.68B
Revenue (ttm)	16.14B
Net Income (ttm)	-12.41B
Shares Out	31.91M
EPS (ttm)	-493.72
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	432,836
Average Volume	352,442
Open	20,000
Previous Close	19,890
Day's Range	20,000 - 21,750
52-Week Range	5,030 - 26,000
Beta	0.10
RSI	59.58
Earnings Date	Mar 19, 2026

About JS Link

JS Link, Inc., a genome-based biotechnology company, focuses on the research and development of genome analysis services in South Korea and internationally. Its next generation sequencing services include whole genome sequencing, De Novo sequencing, whole exome/targeted sequencing, transcriptome sequencing, epigenome sequencing, and single-cell RNA sequencing. The company also provides microarray services, such as DNA and microarray RNA analysis; Fluidigm BioMark System, an automated PCR/qPCR system; TaqMan assay; and SNaPshot assay. In additio...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2000
• Employees: 84
• Stock Exchange: KOSDAQ
• Ticker Symbol: 127120

Financial Performance

In 2024, JS Link's revenue was 15.91 billion, a decrease of -27.52% compared to the previous year's 21.95 billion. Losses were -10.80 billion, 93.0% more than in 2023.